Cor­rect­ed: Cardiff’s stock jumps af­ter shar­ing promis­ing PhII da­ta for its PLK1 in­hibitor in pan­cre­at­ic can­cer

Cardiff On­col­o­gy saw its stock rise af­ter it an­nounced pos­i­tive Phase II da­ta from its PLK1 in­hibitor on­va­nsert­ib in sec­ond-line metasta­t­ic pan­cre­at­ic duc­tal ade­no­car­ci­no­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER